LV10050B - Oral anticoagulant/platelet inhibitor low dose formulation - Google Patents

Oral anticoagulant/platelet inhibitor low dose formulation Download PDF

Info

Publication number
LV10050B
LV10050B LVP-93-275A LV930275A LV10050B LV 10050 B LV10050 B LV 10050B LV 930275 A LV930275 A LV 930275A LV 10050 B LV10050 B LV 10050B
Authority
LV
Latvia
Prior art keywords
amount
warfarin
coated
released
acetylsalicylic acid
Prior art date
Application number
LVP-93-275A
Other languages
English (en)
Latvian (lv)
Other versions
LV10050A (lv
Inventor
William Joseph Addicks
Joseph A Mollica
Gary Howard Slatko
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of LV10050A publication Critical patent/LV10050A/xx
Publication of LV10050B publication Critical patent/LV10050B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
LVP-93-275A 1989-09-18 1993-05-04 Oral anticoagulant/platelet inhibitor low dose formulation LV10050B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/408,394 US5041430A (en) 1989-09-18 1989-09-18 Oral anticoagulant/platelet inhibitor low dose formulation
PCT/US1990/004950 WO1991004031A1 (en) 1989-09-18 1990-09-05 Oral anticoagulant/platelet inhibitor low dose formulation

Publications (2)

Publication Number Publication Date
LV10050A LV10050A (lv) 1994-05-10
LV10050B true LV10050B (en) 1995-02-20

Family

ID=23616120

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-275A LV10050B (en) 1989-09-18 1993-05-04 Oral anticoagulant/platelet inhibitor low dose formulation

Country Status (22)

Country Link
US (1) US5041430A (no)
EP (1) EP0493408B1 (no)
JP (1) JPH05501109A (no)
KR (1) KR950008307B1 (no)
AT (1) ATE137972T1 (no)
AU (1) AU635881B2 (no)
CA (1) CA2065347A1 (no)
CZ (1) CZ454090A3 (no)
DE (1) DE69027036D1 (no)
FI (1) FI921134A (no)
GR (1) GR1001131B (no)
HU (1) HUT62488A (no)
IE (1) IE903356A1 (no)
IL (1) IL95721A (no)
LV (1) LV10050B (no)
MA (1) MA21953A1 (no)
MX (1) MX173727B (no)
NO (1) NO920946L (no)
NZ (1) NZ235337A (no)
PT (1) PT95343B (no)
WO (1) WO1991004031A1 (no)
ZA (1) ZA907431B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5635477A (en) * 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
CA2100836C (en) * 1993-07-19 1998-02-03 Bernard Charles Sherman PHARMACEUTICAL COMPOSITION
CA2218696A1 (en) * 1995-04-19 1996-10-24 L. Jackson Ii Roberts Compositions, kits and methods for administration of antilipemic and an ti-platelet aggregation drugs
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
IT1312088B1 (it) * 1999-04-21 2002-04-04 Altergon Sa Cerotto per uso topico contenente eparina e diclofenac.
US8173164B2 (en) * 1999-06-17 2012-05-08 Gruenenthal Gmbh Oral administration forms for administering a fixed tramadol and diclofenac combination
AU2002226986A1 (en) * 2000-12-01 2002-06-11 Rheologics, Inc. In vivo delivery methods and compositions
AU2002306461A1 (en) * 2001-03-28 2002-10-15 Rheologics, Inc. In vivo delivery methods and compositions
US20050119238A1 (en) * 2002-03-01 2005-06-02 Baron John A. Compositions and methods for preventing sporadic neoplasia in colon
EP1589930A2 (en) * 2003-01-08 2005-11-02 Flacco-Nesselroad Family Trust Combination therapy for anticoagulation
CZ20032854A3 (cs) * 2003-10-17 2005-05-18 Pliva - Lachema A.S. Způsob přípravy dávkových jednotek pevné lékové formy obsahujících jako účinnou látku sodnou sůl warfarinu
EA200600626A1 (ru) * 2003-10-20 2007-02-27 Тева Фармасьютикал Индастриес Лтд. Композиция и лекарственная форма продолжительного выделения леводопы
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
CA2566310C (en) * 2004-05-21 2014-05-13 Lawrence Solomon Scored pharmaceutical tablets comprising a plurality of segments
US20060003000A1 (en) * 2004-07-01 2006-01-05 Lawrence Solomon Adhesively bonded dosage form
US7838031B2 (en) * 2004-05-21 2010-11-23 Lawrence Solomon Method of administering a partial dose using a segmented pharmaceutical tablet
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
US8057820B2 (en) * 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
JP4613590B2 (ja) 2004-11-16 2011-01-19 セイコーエプソン株式会社 実装基板及び電子機器
WO2008082542A1 (en) * 2006-12-19 2008-07-10 Institute For Therapeutic Research, Inc. Combination of vitamin k and vitamin k antagonist such as r-isomer of warfarin, phenprocoumon or r-isomer of phenprocoumon as anticoagulant therapy
US20110041725A1 (en) * 2007-06-19 2011-02-24 Daniel Rittschof Anticoagulants as antifouling agents
DE102008014237A1 (de) * 2008-03-14 2009-09-17 J. Rettenmaier & Söhne Gmbh + Co. Kg Direktverpressbares Tablettierhilfsmittel
JP5529404B2 (ja) * 2008-09-05 2014-06-25 東和薬品株式会社 アスピリン腸溶錠
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
LV14606B (lv) 2011-05-17 2013-01-20 Tetra, Sia Jauns XII faktora inhibitors
CZ304136B6 (cs) * 2012-06-27 2013-11-13 Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta Zpusob prípravy pevné lékové formy se sodnou solí warfarinu ve forme klathrátu izopropanolu
JP6304751B2 (ja) * 2014-03-24 2018-04-04 日新製薬株式会社 ワルファリン含有固形製剤及びその製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2265273A1 (en) * 1974-03-29 1975-10-24 Zootherap Laboratoires Anticoagulant-contg. rodenticidal compsn. - contg. (acetyl) salicyclic acid or salt as synergist
LU77353A1 (no) * 1977-05-16 1979-01-19
GB2038625B (en) * 1978-12-29 1983-01-12 Parcor Therapeutic composition having an antithrombotic and antiblood-platelet-aggregating activity
DE2860430D1 (en) * 1977-10-08 1981-02-26 Beecham Group Ltd Antithrombotic compositions containing benzisothiazolones
SU1050708A1 (ru) * 1981-04-27 1983-10-30 Горьковский государственный медицинский институт им.С.М.Кирова Способ лечени гиперкоагул ции при коронарном атеросклерозе
US4444777A (en) * 1981-07-30 1984-04-24 Bristol-Myers Company Pharmaceutical compositions of anagrelide and sulfinpyrazone
ATE50497T1 (de) * 1984-07-21 1990-03-15 Hoechst Ag Kombinationspraeparat aus pyrimido-pyrimidinen und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung.

Also Published As

Publication number Publication date
GR1001131B (el) 1993-04-28
NO920946D0 (no) 1992-03-11
WO1991004031A1 (en) 1991-04-04
MA21953A1 (fr) 1991-04-01
KR920703046A (ko) 1992-12-17
PT95343A (pt) 1991-08-14
IL95721A (en) 1995-07-31
ZA907431B (en) 1992-05-27
EP0493408A4 (en) 1992-10-07
CA2065347A1 (en) 1991-03-19
MX173727B (es) 1994-03-24
FI921134A0 (fi) 1992-03-17
US5041430A (en) 1991-08-20
ATE137972T1 (de) 1996-06-15
GR900100702A (en) 1992-01-20
NZ235337A (en) 1993-05-26
LV10050A (lv) 1994-05-10
KR950008307B1 (ko) 1995-07-27
EP0493408B1 (en) 1996-05-15
JPH05501109A (ja) 1993-03-04
IE903356A1 (en) 1991-04-10
DE69027036D1 (de) 1996-06-20
HUT62488A (en) 1993-05-28
EP0493408A1 (en) 1992-07-08
IL95721A0 (en) 1991-06-30
NO920946L (no) 1992-03-11
AU635881B2 (en) 1993-04-01
PT95343B (pt) 1998-06-30
AU6330690A (en) 1991-04-18
FI921134A (fi) 1992-03-17
CZ454090A3 (en) 1996-11-13

Similar Documents

Publication Publication Date Title
US5041430A (en) Oral anticoagulant/platelet inhibitor low dose formulation
US5122384A (en) Oral once-per-day organic nitrate formulation which does not induce tolerance
US4904476A (en) Formulations providing three distinct releases
US4794001A (en) Formulations providing three distinct releases
US4728512A (en) Formulations providing three distinct releases
CA2604617C (en) Composition containing anti-dementia drug
KR101207618B1 (ko) 심혈관계 질환 치료용 약제학적 제제
EP1581194B1 (en) Multilayered tablet containing pravastatin and aspirin and method
EP1071403A1 (en) Pharmaceutical composition containing a statin and aspirin
US20060246003A1 (en) Composition containing anti-dementia drug
KR20120105317A (ko) 안정성이 개선된 복합제제
US5589190A (en) Sustained-release compositions of alfuzosin hydrochloride
EP1673073A1 (en) Sustained-release formulations
US20080241240A1 (en) Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
JPH08333259A (ja) スクラルファート含有製剤組成物
EP4069207A1 (en) Modified release pharmaceutical compositions of riociguat
WO2003057198A1 (fr) Compositions pharmaceutiques a liberation modifiee
HU211938A9 (hu) Koagulációt és vérlemezke-működést gátló hatóanyagokat kis dózisban tartalmazó, orális adagolású gyógyszerkészítmények Az átmeneti oltalom a 2-24. igénypontokra vonatkozik.
KR20070058296A (ko) Ace저해제와 스타틴류 약물의 복합제제 조성물 및 그의제조방법